A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 825M | 825M | 901M | 861M | 765M | 482M |
| Net Income | 148M | 148M | 185M | 210M | 181M | 70M |
| EPS | $2.88 | $2.88 | $3.47 | $3.93 | $3.26 | - |
| Free Cash Flow | 89M | 89M | 66M | 197M | 129M | 8.7M |
| ROIC | 21.0% | 21.7% | 32.4% | 40.8% | 35.3% | 15.3% |
| Gross Margin | 55.0% | 55.0% | 56.6% | - | - | - |
| Debt/Equity | 0.20 | 0.20 | 0.12 | 0.12 | 0.15 | 0.21 |
| Dividends/Share | $1.19 | $1.19 | $1.40 | $1.01 | $0.45 | - |
| Operating Income | 194M | 194M | 239M | 269M | 214M | 86M |
| Operating Margin | 23.5% | 23.5% | 26.6% | 31.3% | 28.0% | 17.8% |
| ROE | 23.9% | 24.6% | 32.6% | 38.1% | 36.7% | 16.3% |
| Shares Outstanding | 51M | 51M | 53M | 54M | 55M | - |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 482M | 765M | 861M | 901M | 825M | 825M |
| Gross Margin | N/A | N/A | N/A | 56.6% | 55.0% | 55.0% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | 271M | 260M | 260M |
| EBIT | 86M | 214M | 269M | 239M | 194M | 194M |
| Op. Margin | 17.8% | 28.0% | 31.3% | 26.6% | 23.5% | 23.5% |
| Net Income | 70M | 181M | 210M | 185M | 148M | 148M |
| Net Margin | 14.5% | 23.6% | 24.4% | 20.5% | 17.9% | 17.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 15.3% | 35.3% | 40.8% | 32.4% | 21.7% | 21.0% |
| ROE | 16.3% | 36.7% | 38.1% | 32.6% | 24.6% | 23.9% |
| ROA | 10.6% | 23.7% | 23.5% | 20.6% | 16.7% | 16.5% |
| Cash Flow | ||||||
| Op. Cash Flow | 54M | 176M | 250M | 123M | 149M | 149M |
| Free Cash Flow | 8.7M | 129M | 197M | 66M | 89M | 89M |
| Owner Earnings | 31M | 149M | 226M | 97M | 119M | 119M |
| CapEx | 45M | 47M | 53M | 57M | 61M | 61M |
| Maint. CapEx | 23M | 25M | 24M | 26M | 30M | 30M |
| Growth CapEx | 23M | 22M | 29M | 30M | 30M | 30M |
| D&A | 23M | 25M | 24M | 26M | 30M | 30M |
| CapEx/OCF | 83.9% | 26.9% | 21.3% | 46.3% | 40.5% | 40.5% |
| Capital Allocation | ||||||
| Dividends Paid | 11M | 25M | 54M | 75M | 61M | 61M |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | 1.4% |
| Share Buybacks | 43M | 93M | 186M | 145M | 97M | 97M |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% |
| Stock-Based Comp | 0 | 1.7M | 0 | N/A | N/A | N/A |
| Debt Repayment | 15M | 7.3M | 7.1M | 15M | 56M | 56M |
| Balance Sheet | ||||||
| Net Debt | 28M | -33M | -65M | 44M | 94M | 94M |
| Cash & Equiv. | 61M | 117M | 132M | 27M | 29M | 29M |
| Long-Term Debt | N/A | N/A | N/A | 57M | 98M | 98M |
| Debt/Equity | 0.21 | 0.15 | 0.12 | 0.12 | 0.20 | 0.20 |
| Interest Coverage | 69.7 | 200.4 | 301.4 | 232.3 | 76.4 | 76.4 |
| Equity | 429M | 556M | 549M | 586M | 618M | 618M |
| Total Assets | 660M | 865M | 925M | 868M | 899M | 899M |
| Total Liabilities | 231M | 309M | 376M | 278M | 271M | 271M |
| Intangibles | N/A | N/A | N/A | 37M | 37M | 37M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 278M | 373M | 347M | 336M | 360M | 360M |
| Current Assets | 419M | 598M | 656M | 553M | 529M | 529M |
| Current Liabilities | 141M | 225M | 309M | 217M | 169M | 169M |
| Per Share Data | ||||||
| EPS | N/A | 3.26 | 3.93 | 3.47 | 2.88 | 2.88 |
| Owner EPS | N/A | 2.70 | 4.22 | 1.81 | 2.32 | 2.32 |
| Book Value | N/A | 10.02 | 10.26 | 11.00 | 12.06 | 12.06 |
| Cash Flow/Share | N/A | 3.18 | 4.67 | 2.31 | 2.91 | 3.48 |
| Dividends/Share | N/A | 0.45 | 1.01 | 1.40 | 1.19 | 1.19 |
| Shares Out. | N/A | 55.5M | 53.5M | 53.2M | 51.3M | 51.3M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 29.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 48.4 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 22.6 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 7.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 5.2 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | 2.1% |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 4.3B |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.85 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.85 |
LABORATORIOS FARMACEUTICOS ROVI S.A passes 5 of 9 quality checks, suggesting mixed fundamentals.
The company's 5-year average ROIC is 29.1% with a gross margin of 55.8%. Total shareholder yield (dividends + buybacks) is 3.7%.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a 5-year average return on invested capital (ROIC) of 29.1%. This indicates strong capital allocation and a potential competitive advantage.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a market capitalization of $4.3B. It is classified as a mid-cap stock.
Yes, LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) pays a dividend with a trailing twelve-month yield of 1.42%. The company also returns capital through share buybacks, with a buyback yield of 2.25%.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) reported annual revenue of $825 million in its most recent fiscal year, based on SEC EDGAR filings.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a net profit margin of 17.9%. This is a healthy margin.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) generated $89 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a debt-to-equity ratio of 0.20. This indicates a conservatively financed balance sheet.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) reported earnings per share (EPS) of $2.88 in its most recent fiscal year.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a return on equity (ROE) of 24.6%. This indicates the company generates strong returns for shareholders.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a 5-year average gross margin of 55.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LABORATORIOS FARMACEUTICOS ROVI S.A (ROVI-MC) has a book value per share of $12.06, based on its most recent annual SEC filing.